Brendan Teehan - 23 Feb 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, Head of Commercial
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
23 Feb 2022
Transactions value $
-$11,234
Form type
4
Filing time
25 Feb 2022, 16:45:08 UTC
Previous filing
10 Jan 2022
Next filing
07 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +1.11K +61.86% $0.00 2.89K 23 Feb 2022 Direct
transaction ACAD Common Stock Sale -$11.2K -472 -16.31% $23.80 2.42K 23 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 +1.11K +49.93% $0.00 3.32K 23 Feb 2022 Common Stock 1.11K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in four equal annual installments beginning February 23 2022.